Skip to main content

Developing Treatments For Lysosomal Storage Disorders

Company Overview

Polaryx Therapeutics is a clinical-stage biotechnology company developing patient-friendly small molecule and gene therapy treatments for lysosomal storage disorders (LSDs), a group of rare inherited diseases with high unmet medical need. Our company’s mission is to accelerate the availability of treatments for patients and families living with these disorders using innovative therapeutic approaches.

Doctor with Patient

What We Do

Polaryx has a patient-first research and development approach, pursuing non-invasive therapeutic alternatives including:

  • Orally-available small molecule therapies aimed at promoting lysosome biogenesis, reducing neuroinflammation, and enhancing neuronal survival.
  • A gene therapy candidate formulated for intranasal administration to be used in combination with small molecules.
Preclinical studies conducted with collaborators (Rush University Medical Center) have shown improvements in motor and cognitive functions and increased life expectancy in animal models of lysosomal storage disorders.

  • Hands
  • Running
  • Ring
  • Laughter

Latest News

View all press releases

Latest Presentation

Explore the latest investor presentation to gain insights into Polaryx’s financial performance, strategic initiatives, and growth prospects. This comprehensive overview offers key information to help investors understand Polaryx’s market positioning and future opportunities.

View Investor Presentation

Sign up for Email Alerts

Stay connected and get the latest company news delivered to your inbox.

IR Contacts

Corporate Headquarters

Polaryx Therapeutics, Inc
140 East Ridgewood Avenue
Suite #415, South Tower
Paramus, NJ 07652
(201) 940-7236
info@polaryx.com

Investor Contact

CORE IR
(212) 655-0924
investor@polaryx.com

Transfer Agent

Equiniti Trust Company, LLC
28 Liberty Street, 53rd Floor, New York, NY 10005
(800) 401-1957
(651) 450-4064
https://equiniti.com/global/